The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks ...

Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

The fine of €462.6 million ($503 million) is believed to be the largest imposed on a pharma company for breaking antitrust ...

The EU Commission said Teva's actions may have prevented significant savings by countries across Europe, with other versions of the drug possibly 80% cheaper than Copaxone. Teva will have to pay a ...